Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism
Mohammed A. S. Abourehab, Alaa M. Alqahtani, Bahaa G. M. Youssif, et al.
Molecules (2021) Vol. 26, Iss. 21, pp. 6677-6677
Open Access | Times Cited: 122

Showing 1-25 of 122 citing articles:

A Comprehensive Overview of Globally Approved JAK Inhibitors
Ahmed M. Shawky, Faisal A. Almalki, Ashraf N. Abdalla, et al.
Pharmaceutics (2022) Vol. 14, Iss. 5, pp. 1001-1001
Open Access | Times Cited: 177
Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities
Tanzida Zubair, Debasish Bandyopadhyay
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2651-2651
Open Access | Times Cited: 98
DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts
Mariana Shumliakivska, Guillermo Luxán, Inga Hemmerling, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 18
The Role of Oxidative Stress in Tumorigenesis and Progression
Kexin Li, Zhangyuzi Deng, Chunran Lei, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 441-441
Open Access | Times Cited: 13
Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer
Manzar Alam, Shoaib Alam, Anas Shamsi, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 59
Targeting EGFR in melanoma – The sea of possibilities to overcome drug resistance
Joanna Pastwińska, Kaja Karaś, Iwona Karwaciak, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 4, pp. 188754-188754
Open Access | Times Cited: 35
The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies
George Mihai Niţulescu, Gheorghe Stancov, Oana Cristina Șeremet, et al.
Molecules (2023) Vol. 28, Iss. 14, pp. 5359-5359
Open Access | Times Cited: 28
Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor
Yuesheng Zhang
Pharmacological Reviews (2023) Vol. 75, Iss. 6, pp. 1218-1232
Open Access | Times Cited: 23
Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma
Manzar Alam, Gulam Mustafa Hasan, Sayed M. Eldin, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 161, pp. 114452-114452
Open Access | Times Cited: 22
Pareto optimization to accelerate multi-objective virtual screening
Jenna C. Fromer, David Graff, Connor W. Coley
Digital Discovery (2024) Vol. 3, Iss. 3, pp. 467-481
Open Access | Times Cited: 8
Profiling of ERBB receptors and downstream pathways reveals selectivity and hidden properties of ERBB4 antagonists
Lukša Popović, Jan P. Wintgens, Yuxin Wu, et al.
iScience (2024) Vol. 27, Iss. 2, pp. 108839-108839
Open Access | Times Cited: 7
Chimeric Antigen Receptor T Cell and Chimeric Antigen Receptor NK Cell Therapy in Pediatric and Adult High-Grade Glioma—Recent Advances
Adrian Kowalczyk, Julia Zarychta, Anna Marszołek, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 623-623
Open Access | Times Cited: 6
THE ROLE OF MOLECULAR BIOMARKERS IN THE DIAGNOSIS, PROGNOSIS, AND TREATMENT STRATIFICATION OF ORAL SQUAMOUS CELL CARCINOMA: A COMPREHENSIVE REVIEW
Swaathi Ravindran, R Srinivasan, Raghupathy Karthikeyan, et al.
The Journal of Liquid Biopsy (2025), pp. 100285-100285
Closed Access
Clinical evaluation and outcome in heart failure patients receiving chemotherapy with different anti‐cancer agents
Tomiko Sunaga, Takahiro Okada, Yoshitaka Iso, et al.
ESC Heart Failure (2025)
Open Access
Design, synthesis, and apoptotic antiproliferative action of new benzimidazole/1,2,3-triazole hybrids as EGFR inhibitors
Abubakar Ahmed, Anber F. Mohammed, Zainab M. Almarhoon, et al.
Frontiers in Chemistry (2025) Vol. 12
Open Access
Development and validation of an ultrasensitive qPCR method to identify and quantify EGFR T790M in cell-free DNA
Shaoji Yuan, Nan Jia, Guofu Lu, et al.
Bioanalysis (2025) Vol. 17, Iss. 1, pp. 49-62
Closed Access
Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting
Alessandra Spada, Sandrine Gerber‐Lemaire
Nanomaterials (2025) Vol. 15, Iss. 3, pp. 158-158
Open Access
Synthesis, Biological Evaluation and Molecular Modeling Studies of Quinazolin-4(3h)-One and Benzenesulfonamide Hybrids as Potential Anticancer Agents
Emre Kadir Ayan, Ali Ergüç, Ege Arzuk, et al.
(2025)
Closed Access
Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: A review
Chao Wang, Yujing Zhang, Wujun Chen, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 4, pp. 188927-188927
Closed Access | Times Cited: 18
The anticancer and EGFR-TK/CDK-9 dual inhibitory potentials of new synthetic pyranopyrazole and pyrazolone derivatives: X-ray crystallography, in vitro , and in silico mechanistic investigations
Arafa Musa, Saleh Ihmaid, David L. Hughes, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 41, Iss. 21, pp. 12411-12425
Open Access | Times Cited: 17
Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma
Gulam Mustafa Hasan, Md. Imtaiyaz Hassan, Sukhwinder Singh Sohal, et al.
ACS Omega (2023) Vol. 8, Iss. 30, pp. 26685-26698
Open Access | Times Cited: 15
Design, Synthesis, and Antiproliferative Activity of New 5-Chloro-indole-2-carboxylate and Pyrrolo[3,4-b]indol-3-one Derivatives as Potent Inhibitors of EGFRT790M/BRAFV600E Pathways
Lamya H. Al-Wahaibi, Anber F. Mohammed, Mostafa Abdelrahman, et al.
Molecules (2023) Vol. 28, Iss. 3, pp. 1269-1269
Open Access | Times Cited: 14
In silico and in vitro evaluation of novel carbothioamide-based and heterocyclic derivatives of 4-(tert-butyl)-3-methoxybenzoic acid as EGFR tyrosine kinase allosteric site inhibitors
Imad M. Malik AL-Rubay, Ammar A. Razzak Mahmood, Lubna H. Tahtamouni, et al.
Results in Chemistry (2024) Vol. 7, pp. 101329-101329
Open Access | Times Cited: 5
Single molecule tracking based drug screening
D. Watanabe, Michio Hiroshima, Masato Yasui, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
DNA Damage Response Mechanisms in Head and Neck Cancer: Significant Implications for Therapy and Survival
Chara Papalouka, Maria Adamaki, Panagiota Batsaki, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2760-2760
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top